Cargando…

Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study

BACKGROUND: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic platinum (Pt) exposure) was evaluated using a population pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Royer, B, Kalbacher, E, Onteniente, S, Jullien, V, Montange, D, Piedoux, S, Thiery-Vuillemin, A, Delroeux, D, Pili-Floury, S, Guardiola, E, Combe, M, Muret, P, Nerich, V, Heyd, B, Chauffert, B, Kantelip, J-P, Pivot, X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273361/
https://www.ncbi.nlm.nih.gov/pubmed/22173671
http://dx.doi.org/10.1038/bjc.2011.557
_version_ 1782222925799096320
author Royer, B
Kalbacher, E
Onteniente, S
Jullien, V
Montange, D
Piedoux, S
Thiery-Vuillemin, A
Delroeux, D
Pili-Floury, S
Guardiola, E
Combe, M
Muret, P
Nerich, V
Heyd, B
Chauffert, B
Kantelip, J-P
Pivot, X
author_facet Royer, B
Kalbacher, E
Onteniente, S
Jullien, V
Montange, D
Piedoux, S
Thiery-Vuillemin, A
Delroeux, D
Pili-Floury, S
Guardiola, E
Combe, M
Muret, P
Nerich, V
Heyd, B
Chauffert, B
Kantelip, J-P
Pivot, X
author_sort Royer, B
collection PubMed
description BACKGROUND: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic platinum (Pt) exposure) was evaluated using a population pharmacokinetic analysis. METHODS: Data from 55 patients treated with cisplatin-based IP perioperative chemotherapy with (n=26) or without (n=29) epinephrine were analysed using NONMEM. RESULTS: Epinephrine halves clearance between peritoneum and serum (IPCL) and increases the Pt central volume of distribution, IP exposure and penetration in tissue. IPCL has a better predictive value than any other parameter with respect to renal toxicity. CONCLUSION: This confirms that IPCL could be useful in assessing renal toxicity. As IPCL is also linked to tissue penetration and IP exposure, it may be proposed as biomarker. In addition to a Bayesian estimation, we propose a single-sample calculation-way to assess it. Prospective studies are needed to validate IPCL as a biomarker in this context.
format Online
Article
Text
id pubmed-3273361
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-32733612013-01-31 Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study Royer, B Kalbacher, E Onteniente, S Jullien, V Montange, D Piedoux, S Thiery-Vuillemin, A Delroeux, D Pili-Floury, S Guardiola, E Combe, M Muret, P Nerich, V Heyd, B Chauffert, B Kantelip, J-P Pivot, X Br J Cancer Clinical Studies BACKGROUND: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic platinum (Pt) exposure) was evaluated using a population pharmacokinetic analysis. METHODS: Data from 55 patients treated with cisplatin-based IP perioperative chemotherapy with (n=26) or without (n=29) epinephrine were analysed using NONMEM. RESULTS: Epinephrine halves clearance between peritoneum and serum (IPCL) and increases the Pt central volume of distribution, IP exposure and penetration in tissue. IPCL has a better predictive value than any other parameter with respect to renal toxicity. CONCLUSION: This confirms that IPCL could be useful in assessing renal toxicity. As IPCL is also linked to tissue penetration and IP exposure, it may be proposed as biomarker. In addition to a Bayesian estimation, we propose a single-sample calculation-way to assess it. Prospective studies are needed to validate IPCL as a biomarker in this context. Nature Publishing Group 2012-01-31 2011-12-15 /pmc/articles/PMC3273361/ /pubmed/22173671 http://dx.doi.org/10.1038/bjc.2011.557 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Studies
Royer, B
Kalbacher, E
Onteniente, S
Jullien, V
Montange, D
Piedoux, S
Thiery-Vuillemin, A
Delroeux, D
Pili-Floury, S
Guardiola, E
Combe, M
Muret, P
Nerich, V
Heyd, B
Chauffert, B
Kantelip, J-P
Pivot, X
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
title Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
title_full Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
title_fullStr Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
title_full_unstemmed Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
title_short Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
title_sort intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
topic Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273361/
https://www.ncbi.nlm.nih.gov/pubmed/22173671
http://dx.doi.org/10.1038/bjc.2011.557
work_keys_str_mv AT royerb intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT kalbachere intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT ontenientes intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT jullienv intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT montanged intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT piedouxs intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT thieryvuillemina intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT delroeuxd intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT piliflourys intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT guardiolae intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT combem intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT muretp intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT nerichv intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT heydb intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT chauffertb intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT kantelipjp intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy
AT pivotx intraperitonealclearanceasapotentialbiomarkerofcisplatinafterintraperitonealperioperativechemotherapyapopulationpharmacokineticstudy